Outlook Therapeutics

OTLK

Market cap $46.2M

Overview Fund Activity

1.04 USD

-0.05

4.59%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.06

+0.02

1.92%

1 day

-4.59%

5 days

12.49%

1 month

-50.24%

3 months

-43.48%

6 months

-32.47%

Year to date

-49.51%

1 year

-83.98%

5 years

-91.62%

10 years

-99.85%

About: Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Employees: 23

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

10% more capital invested

Capital invested by funds: $8.64M [Q1] → $9.5M (+$852K) [Q2]

2% more funds holding

Funds holding: 63 [Q1] → 64 (+1) [Q2]

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

4.04% less ownership

Funds ownership: 21.72% [Q1] → 17.68% (-4.04%) [Q2]

11% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 18

24% less call options, than puts

Call options by funds: $31K | Put options by funds: $41K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$1

-4% downside

Avg. target

$2

92% upside

High target

$3

188% upside

2 analyst ratings

0 positive

0%

2 neutral

100%

0 negative

0%

HC Wainwright & Co. Douglas Tsao	$1	Neutral Downgraded	29 Aug 2025
Chardan Capital Daniil Gataulin	$3	Neutral Maintained	28 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about OTLK published over the past 30 days

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the EURETINA Innovation Spotlight being held as part of the 25th EURETINA Congress on September 3, 2025 in Le Palais des Congrès, Paris.

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Outlook Therapeutics Requests Type A Meeting with FDA

ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that a Type A Meeting request has been submitted to the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

Outlook Therapeutics Requests Type A Meeting with FDA

Zacks Investment Research

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Shares of Outlook Therapeutics fell sharply on Thursday after the US Food and Drug Administration (FDA) rejected the company's application for its experimental eye drug ONS-5010, a proposed treatment for wet age-related macular degeneration (wet AMD).

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Outlook Therapeutics, Inc. OTLK stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

US FDA declines to approve Outlook Therapeutics' drug for eye condition

The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' experimental drug to treat a type of eye condition that causes blurred vision, the company said on Thursday.

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its biologics license application (BLA) resubmission, indicating that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration (wet AMD).

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

FDA approval for Lytenava might come next week, I see Outlook Therapeutics at a pivotal inflection point, offering a rare asymmetric risk/reward setup. Lytenava's European approval, decade-long exclusivity, and initial sales validate its regulatory and commercial path, providing a strong foundation for US launch. Financials are tight, cash burn is high, and revenue is minimal, but US approval could rapidly shift the outlook, unlocking a much larger market.

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Zacks Investment Research

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.83 per share a year ago.

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 and provided a corporate update.

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™